scholarly journals Long-Term Clinical Outcome of Gastric MALT Lymphoma After Eradication of Helicobacter pylori : A Multicenter Retrospective Follow-up Study of 423 Patients in Japan

2011 ◽  
Vol 140 (5) ◽  
pp. S-872
Author(s):  
Shotaro Nakamura ◽  
Katsunori Iijima ◽  
Shouko Ono ◽  
Masahiro Tajika ◽  
Akira Tari ◽  
...  
Gut ◽  
2011 ◽  
Vol 61 (4) ◽  
pp. 507-513 ◽  
Author(s):  
Shotaro Nakamura ◽  
Toshiro Sugiyama ◽  
Takayuki Matsumoto ◽  
Katsunori Iijima ◽  
Shouko Ono ◽  
...  

2000 ◽  
Vol 118 (4) ◽  
pp. A764
Author(s):  
In Sung Song ◽  
You Sun Kim ◽  
Il Ju Choi ◽  
Joo Sung Kim ◽  
Hyun Chae Jung ◽  
...  

2018 ◽  
Vol 11 (3) ◽  
pp. 187-193 ◽  
Author(s):  
Petruta Violeta Filip ◽  
◽  
Denisa Cuciureanu ◽  
Laura Sorina Diaconu ◽  
Ana Maria Vladareanu ◽  
...  

Primary gastric lymphoma (PGL) represents a rare pathology, which can be easily misdiagnosed because of unspecific symptoms of the digestive tract. Histologically, PGL can vary from indolent marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) to aggressive diffuse large B-cell lymphoma (DLBCL). During the years, clinical trials revealed the important role of Helicobacter pylori (H. pylori) in the pathogenesis of gastric MALT lymphoma. Infection with Helicobacter pylori is an influential promoter of gastric lymphomagenesis initiation. Long-term studies revealed that eradication therapy could regress gastric lymphomas.


2014 ◽  
Vol 25 ◽  
pp. iv333
Author(s):  
M. Tajika ◽  
Y. Niwa ◽  
T. Tanaka ◽  
M. Ishihara ◽  
N. Mizuno ◽  
...  

2000 ◽  
Vol 118 (4) ◽  
pp. A1293
Author(s):  
Alberto Pilotto ◽  
Marilisa Franceschi ◽  
Gioacchino Leandro ◽  
Romeo Novello ◽  
Francesco Di Mario ◽  
...  

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2583-2583 ◽  
Author(s):  
Claudio Chini ◽  
Graziella Pinotti ◽  
Anastasios Stathis ◽  
Ilaria Proserpio ◽  
Francesco Bertoni ◽  
...  

Abstract Background: Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach is often associated with Helicobacter pylori (Hp) infection and Hp eradication therapy is widely accepted as initial treatment. The aim of this study is to report the clinical characteristics and long term outcome in a large series of patients with gastric MALT lymphoma exclusively treated with Hp eradication therapy. Methods: 105 newly diagnosed gastric MALT lymphoma patients (54 men and 51 women) with median age of 64 years (range 20–94) referred to our institutions between June 1990 and November 2006 were eligible for the study. Staging was performed according to the Lugano staging system. All patients received anti-Hp eradication therapy as initial treatment with standard regimens combining antibiotics (usually Amoxicillin, Clarithromycin and/or Metronidazole) and proton-pump inhibitors (Omeprazole in most cases). Responses, evaluated with regular endoscopic biopsies every 3–6 months were graded according to the Wotherspoon’s histological score system. Results: 100 patients had stage I and 5 patients had stage IIE1 disease. Hp was positive in 83 patients (79.5%) and was eradicated in all positive patients but 19 patients required a second line antibiotic therapy. Symptoms disappeared or markedly diminished and endoscopic features improved in almost all patients after Hp eradication. Histological regression of the gastric lymphoma was achieved in 78 of 102 evaluable patients (76%, 95% C.I.; 67%–84%) with histological complete response (Wotherspoon’s score 0–2) in 66 and partial response (score 3) in 12 patients. Of the 78 patients who achieved a lymphoma regression, the histological remission was consistently confirmed at follow-up endoscopies in 28 patients (36%), while 33 (42%) had histological score fluctuations (from 0–4), sometimes with transient histological relapses followed by spontaneous histological remissions. Ten patients had a frank lymphoma relapse (2 with high-grade transformation) and 7 died in remission for other causes. At a median follow up time of 6.3 years, the overall survival in the entire group is 92% at 5 years (95% C.I.; 84%–96%), 83% at 10 years (95% C.I.; 70%–91%) and 78% at 15 years (95% C.I.; 62%–88%). Only one patient died for lymphoma (after histological transformation). Additional tumors were observed in 22%. A history of autoimmune disease was present in 15% of the patients and did not affect the outcome. Conclusions: Hp eradication usually results in long term disease control, independently of the lymphoma pathological remission status. A watch and wait policy seems safe in patients with local histological relapse with no endoscopic evidence of gross disease.


Sign in / Sign up

Export Citation Format

Share Document